Pomerantz Law Firm Alerts Investors of Class Action Lawsuit Against RxSight, Inc. Over Losses

Investor Alert: Class Action Lawsuit Filed Against RxSight, Inc.

Pomerantz LLP has recently announced the filing of a class action lawsuit against RxSight, Inc. (NASDAQ: RXST), drawing attention from investors who have experienced losses on their investments. For those affected, the firm urges individuals to get in touch with attorney Danielle Peyton at [email protected] or 646-581-9980, toll-free at 888.4-POMLAW (Ext. 7980).

Background of the Class Action

The class action lawsuit against RxSight focuses on whether the company and some of its officers and directors have been involved in securities fraud or any unlawful business practices. This concern arises following RxSight's troubling financial news released on July 8, 2025. The company reported that its Light Delivery Device (LDD) sales and revenues took a significant hit, with a downward adjustment of about $42.5 million for its full year 2025 guidance.

CEO Ronald Kurtz acknowledged that challenges in adoption were a key factor leading to a stall in LDD sales throughout the past quarters. The impact became glaringly evident as RxSight's stock plummeted by nearly 38%, losing $4.84 per share, and closing at $7.95 on July 9, 2025, a day after the unfavorable financial report was made public.

Given the circumstances, investors who acquired RxSight securities during the class period are encouraged to take action by September 22, 2025, to be appointed as Lead Plaintiff in the case.

Firm Overview

Founded by the late Abraham L. Pomerantz, a pioneer in the field of securities class actions, Pomerantz LLP has earned recognition for its work in corporate, securities, and antitrust class litigation. With over 85 years of dedicated service, the firm has successfully secured numerous multimillion-dollar awards for victims of securities fraud and corporate misconduct. Their continued commitment to fight for the rights of investors underscores their reputation in the legal landscape.

For those looking to join the class action or seeking more information, a copy of the complaint is available on the Pomerantz website at www.pomerantzlaw.com.

Conclusion

Investors impacted by RxSight's performance should stay informed and act quickly to protect their interests. Pomerantz LLP stands ready to advocate for those battered by potential fraud within the investment landscape. For details on how to proceed, potential plaintiffs are reminded to include their contact details and stock purchase information when reaching out to the firm.

For further inquiries, contact:
Danielle Peyton
Pomerantz LLP
Email: [email protected]
Phone: 646-581-9980 ext. 7980